What is Mineralys Therapeutics, Inc.'s return on equity?

Mineralys Therapeutics, Inc. (MLYS) reported return on equity of -31% in Q1 2026.

How has Mineralys Therapeutics, Inc.'s return on equity changed year-over-year?

Mineralys Therapeutics, Inc.'s return on equity increased by 45.0% year-over-year, from -56.3% to -31%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Mineralys Therapeutics, Inc. MLYS Return on equity

Return on equity at other companies

Aurinia PharmaceuticalsAUPH

65%+53.8pp

Crinetics PharmaceuticalsCRNX

-39.2%+14.5pp

Stoke Therapeutics, Inc.STOK

-45.6%-66.1pp

ArriVent BioPharma, Inc.AVBP

-55.2%+8.0pp

Kiniksa Pharmaceuticals International, plcKNSA

13.7%+11.3pp

Septerna, Inc.SEPN

-12.2%—

Other financials

Income statement

See full

Operating income-$45.3M-2.0%

Net income-$39.3M+6.8%

EPS (diluted)-$0.47+40.5%

Balance sheet

See full

Cash & equivalents$1.2M-14.6%

Total equity$638.1M+86.8%

Total assets$652.9M+83.9%

Cash flow

See full

Operating cash flow-$39.5M+13.2%

CapEx$15.0K—

Free cash flow-$37.9M+43.3%

Valuation

See full

Market cap$2.26B+124%

Returns & leverage

See full

Current ratio44.3×+17.8×

Where this comes from

Calculated from Mineralys Therapeutics, Inc.’s reported figures.

net income/total stockholders equity=-31%

Based on trailing twelve months.

The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mineralys Therapeutics, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mineralys Therapeutics, Inc.'s return on equity?: Mineralys Therapeutics, Inc. (MLYS) reported return on equity of -31% in Q1 2026.
How has Mineralys Therapeutics, Inc.'s return on equity changed year-over-year?: Mineralys Therapeutics, Inc.'s return on equity increased by 45.0% year-over-year, from -56.3% to -31%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.